Commentary: Durability of SVR in chronic hepatitis C patients treated with peginterferon-A2a/ribavirin in combination with a direct-Acting anti-viral

摘要

In their clinical trial, Rutter et al. reported that triple therapy with direct-acting anti-viral agent (DAA) with peginterferon-a2a/ribavirin demonstrates durable sustained viral response (SVR), similar to the durable SVR rates reported after peginterferon/ribavirin combination therapy. Prior studies of chronic hepatitis C virus (HCV)-infected patients treated with peginter-feron-a2a alone or in combination with ribavirin have shown that SVR rates achieved 24 weeks after completion of therapy were maintained for almost 4 years.